T1DM children | CD4+ TCR Vβ Increased usage | CD4 + TCR Vβ Decreased usage |
---|---|---|
Patient 1 | Vβ5.1 (7.3%, Μ + 2SD) | None |
Patient 2 | Vβ5.3 (5.8%, Μ + 3SD) | None |
Patient 3 | Vβ16 (5%, Μ + 3SD) | None |
Vβ5.1 (7.5%, Μ + 2SD) | ||
Vβ8 (6.5%, Μ + 2SD) | ||
Vβ21.3 (4.1%, Μ + 2SD) | ||
Patient 4 | None | None |
Patient 5 | Vβ16 (5.5%, Μ + 3SD) | Vβ14 (0.7%, Μ-2SD) |
Vβ18 (4.1%, Μ + 3SD) | ||
Vβ11 (3.1%, Μ + 2SD) | ||
Patient 6 | None | None |
Patient 7 | None | None |
Patient 8 | Vβ3 (11.2%, Μ + 3SD) | None |
Patient 9 | Vβ4 (2.6%, Μ + 3SD) | None |
Patient 10 | None | None |
Patient 11 | Vβ4 (2.3%, Μ + 2SD) | None |
Patient 12 | Vβ4 (2.1%, Μ + 2SD) | None |
Patient 13 | None | None |
Patient 14 | Vβ4 (2.2%, Μ + 2SD) | None |
Patient 15 | Vβ5.1 (9.1%, Μ + 3SD) | Vβ20 (0.5%, Μ-2SD) |
Vβ4(3.3%, Μ + 3SD) |